Amsacrine as a topoisomerase II poison: Importance of drug-DNA interactions

Biochemistry

Volumn 51, Issue 8, 2012, Pages 1730-1739

  Ketron, Adam C ^a   Denny, William A ^b   Graves, David E ^c   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ANTI-CANCER AGENTS; DNA BINDING; DNA CLEAVAGE; DNA INTERCALATIONS; DNA-BINDING AGENT; HUMAN TOPOISOMERASE; METHOXY; NON-HODGKIN'S LYMPHOMA; ROTATIONAL FREEDOM; STRUCTURE-FUNCTION RELATIONSHIP; TERNARY COMPLEX; TOPOISOMERASE II; TOPOISOMERASES;

COMPLEXATION; DNA;

DRUG INTERACTIONS;

ACRIDINE; AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); TOPOISOMERASE IIALPHA; TOPOISOMERASE IIBETA; UNCLASSIFIED DRUG;

ARTICLE; DNA CLEAVAGE; DRUG ACTIVITY; DRUG DNA INTERACTION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMSACRINE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BINDING SITES; DNA; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HUMANS; INTERCALATING AGENTS; KINETICS; MOLECULAR DYNAMICS SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

EID: 84857609733     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi201159b     Document Type: Article

References (50)

1. Deweese, J. E. and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing Nucleic Acids Res. 37, 738-748
2. Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 17, 421-433
3. National Cancer Institute (2011) Clinical Trials. http://www.cancer.gov/ clinicaltrials/search/results?protocolsearchid=9234167.
4. Jehn, U. and Heinemann, V. (1991) New drugs in the treatment of acute and chronic leukemia with some emphasis on m -AMSA Anticancer Res. 11, 705-711
5. Kell, J. (2006) Treatment of relapsed acute myeloid leukaemia Rev. Recent Clin. Trials 1, 103-111
6. Verma, D., Kantarjian, H., Faderl, S., O'Brien, S., Pierce, S., Vu, K., Freireich, E., Keating, M., Cortes, J., and Ravandi, F. (2010) Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome Leuk. Lymphoma 51, 778-782
7. Nelson, E. M., Tewey, K. M., and Liu, L. F. (1984) Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon- m -anisidide Proc. Natl. Acad. Sci. U.S.A. 81, 1361-1365
8. Robinson, M. J. and Osheroff, N. (1990) Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: Inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino)methanesulfon- m -anisidide Biochemistry 29, 2511-2515
9. Robinson, M. J. and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II Biochemistry 30, 1807-1813
10. Sorensen, B. S., Sinding, J., Andersen, A. H., Alsner, J., Jensen, P. B., and Westergaard, O. (1992) Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events J. Mol. Biol. 228, 778-786
11. McClendon, A. K. and Osheroff, N. (2007) DNA topoisomerase II, genotoxicity, and cancer Mutat. Res. 623, 83-97
12. Deweese, J. E., Burgin, A. B., and Osheroff, N. (2008) Using 3′-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIα Biochemistry 47, 4129-4140
13. Nitiss, J. L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy Nat. Rev. Cancer 9, 338-350
14. Marsh, K. L., Willmore, E., Tinelli, S., Cornarotti, M., Meczes, E. L., Capranico, G., Fisher, L. M., and Austin, C. A. (1996) Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β Biochem. Pharmacol. 52, 1675-1685
15. McClendon, A. K. and Osheroff, N. (2006) The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs Biochemistry 45, 3040-3050
16. Withoff, S., de Vries, E. G., Keith, W. N., Nienhuis, E. F., van der Graaf, W. T., Uges, D. R., and Mulder, N. H. (1996) Differential expression of DNA topoisomerase II α and β in P-gp and MRP-negative VM26, m AMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4 Br. J. Cancer 74, 1869-1876
17. Dereuddre, S., Delaporte, C., and Jacquemin-Sablon, A. (1997) Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors Cancer Res. 57, 4301-4308
18. Herzog, C. E., Holmes, K. A., Tuschong, L. M., Ganapathi, R., and Zwelling, L. A. (1998) Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα Cancer Res. 58, 5298-5300
19. Errington, F., Willmore, E., Tilby, M. J., Li, L., Li, G., Li, W., Baguley, B. C., and Austin, C. A. (1999) Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation Mol. Pharmacol. 56, 1309-1316
20. Zwelling, L. A., Michaels, S., Erickson, L. C., Ungerleider, R. S., Nichols, M., and Kohn, K. W. (1981) Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino) methanesulfon- m -anisidide and adriamycin Biochemistry 20, 6553-6563
21. Yang, L., Rowe, T. C., Nelson, E. M., and Liu, L. F. (1985) In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin Cell 41, 127-132
22. Ross, W., Rowe, T., Glisson, B., Yalowich, J., and Liu, L. (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage Cancer Res. 44, 5857-5860
23. Chow, K. C., Macdonald, T. L., and Ross, W. E. (1988) DNA binding by epipodophyllotoxins and N-acyl anthracyclines: Implications for mechanism of topoisomerase II inhibition Mol. Pharmacol. 34, 467-473
24. Baldwin, E. L. and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer Curr. Med. Chem.: Anti-Cancer Agents 5, 363-372
25. Cain, B. F., Seelye, R. N., and Atwell, G. J. (1974) Potential antitumor agents. 14. Acridylmethanesulfonanilides J. Med. Chem. 17, 922-930
26. Cain, B. F., Atwell, G. J., and Denny, W. A. (1975) Potential antitumor agents. 16. 4′-(Acridin-9-ylamino)methanesulfonanilides J. Med. Chem. 18, 1110-1117
27. Waring, M. J. (1976) DNA-binding characteristics of acridinylmethanesulphonanilide drugs: Comparison with antitumour properties Eur. J. Cancer 12, 995-1001
28. Elmore, R. H., Wadkins, R. M., and Graves, D. E. (1988) Cooperative binding of m -AMSA to nucleic acids Nucleic Acids Res. 16, 9707-9719
29. Wadkins, R. M. and Graves, D. E. (1989) Thermodynamics of the interactions of m -AMSA and o -AMSA with nucleic acids: Influence of ionic strength and DNA base composition Nucleic Acids Res. 17, 9933-9946
30. Wadkins, R. M. and Graves, D. E. (1991) Interactions of anilinoacridines with nucleic acids: Effects of substituent modifications on DNA-binding properties Biochemistry 30, 4277-4283
31. Austin, C. A., Marsh, K. L., Wasserman, R. A., Willmore, E., Sayer, P. J., Wang, J. C., and Fisher, L. M. (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ J. Biol. Chem. 270, 15739-15746
32. Worland, S. T. and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae J. Biol. Chem. 264, 4412-4416
33. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints Biochemistry 36, 5934-5939
34. Fortune, J. M. and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage J. Biol. Chem. 273, 17643-17650
35. Baldwin, E. L., Byl, J. A., and Osheroff, N. (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells Biochemistry 43, 728-735
36. O'Reilly, E. K. and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents Biochemistry 41, 7989-7997
37. Fortune, J. M., Velea, L., Graves, D. E., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition Biochemistry 38, 15580-15586
38. Fortune, J. M., Dickey, J. S., Lavrukhin, O. V., Van Etten, J. L., Lloyd, R. S., and Osheroff, N. (2002) Site-specific DNA cleavage by Chlorella virus topoisomerase II Biochemistry 41, 11761-11769
39. Shieh, T. L., Hoyos, P., Kolodziej, E., Stowell, J. G., Baird, W. M., and Byrn, S. R. (1990) Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine J. Med. Chem. 33, 1225-1230
40. Freudenreich, C. H. and Kreuzer, K. N. (1994) Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex Proc. Natl. Acad. Sci. U.S.A. 91, 11007-11011
41. Wu, C. C., Li, T. K., Farh, L., Lin, L. Y., Lin, T. S., Yu, Y. J., Yen, T. J., Chiang, C. W., and Chan, N. L. (2011) Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 333, 459-462
42. Wilstermann, A. M., Bender, R. P., Godfrey, M., Choi, S., Anklin, C., Berkowitz, D. B., Osheroff, N., and Graves, D. E. (2007) Topoisomerase II-drug interaction domains: Identification of substituents on etoposide that interact with the enzyme Biochemistry 46, 8217-8225
43. Bender, R. P., Jablonksy, M. J., Shadid, M., Romaine, I., Dunlap, N., Anklin, C., Graves, D. E., and Osheroff, N. (2008) Substituents on etoposide that interact with human topoisomerase IIα in the binary enzyme-drug complex: Contributions to etoposide binding and activity Biochemistry 47, 4501-4509
44. Pitts, S. L., Jablonksy, M. J., Duca, M., Dauzonne, D., Monneret, C., Arimondo, P. B., Anklin, C., Graves, D. E., and Osheroff, N. (2011) Contributions of the D-ring to the activity of etoposide against human topoisomerase IIα: Potential interactions with DNA in the ternary enzyme-drug-DNA complex Biochemistry 50, 5058-5066
45. Osheroff, N. and Zechiedrich, E. L. (1987) Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: Trapping the covalent enzyme-DNA complex in an active form Biochemistry 26, 4303-4309
46. Bender, R. P., Lindsey, R. H., Jr., Burden, D. A., and Osheroff, N. (2004) N-Acetyl- p -benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison Biochemistry 43, 3731-3739
47. Lindsey, R. H., Bender, R. P., and Osheroff, N. (2005) Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites Chem.-Biol. Interact. 153-154, 197-205
48. Bender, R. P., Lehmler, H. J., Robertson, L. W., Ludewig, G., and Osheroff, N. (2006) Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIα: Altering enzyme function by blocking the N-terminal protein gate Biochemistry 45, 10140-10152
49. Bandele, O. J. and Osheroff, N. (2008) (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases Chem. Res. Toxicol. 21, 936-943
50. Bender, R. P., Ham, A. J., and Osheroff, N. (2007) Quinone-induced enhancement of DNA cleavage by human topoisomerase IIα: Adduction of cysteine residues 392 and 405 Biochemistry 46, 2856-2864